Key result
CentriMag RVAD provides successful right ventricular support for ~300 days post-LVAS without mechanical failure.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
Right ventricular failure (RVF) following implantation of a left ventricular assist system (LVAS) is associated with high morbidity and mortality.( 1-4 ) Numerous centers have reported short-term use of the CentriMag (®) Ventricular Assist System (CVAS) (Levitronix LLC, Waltham, MA) for treatment of cardiogenic shock, decompensated heart failure and right ventricular failure (RVF) following LVAS implantation.( 5-9 ) The present report reviews the clinical course of a patient requiring long-term right ventricular support utilizing the CVAS, following a HeartMate (®) II LVAS (Thoratec Corp. Pleasanton, CA) implantation. Elevated cytotoxic antibody levels complicated the patient's treatment plan by precluding orthotropic heart transplantation. The CVAS operated for 304 days without mechanical difficulty until replaced with the HeartWare (®) Ventricular Assist System (HeartWare Inc. Miramar, FL).
No takes yet. Share an insight, caveat, or question.
Griffith et al. (2011) conducted a case report in Right ventricular failure following LVAS implantation (n=1). CentriMag Ventricular Assist System (CVAS) was evaluated. The CentriMag Ventricular Assist System operated successfully as a right ventricular assist device for 304 days without mechanical difficulty in a patient following LVAS implantation.
Synapse has enriched 10 related papers. Consider them for comparative context: